RxDoctor Payments DataLook up a doctor →

Jonathan Black, MD

Allergy & Immunology · Columbia, SCNPI 1659588382

Payments from drug & device makers

$9,323in general payments, 2019–2025

Across 412 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • AstraZeneca$975
  • Octapharma USA, Inc.$761
  • CSL Behring$752
  • GSK$711
  • Biocryst US Sales Co., LLC$611
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,97796%
  • Education$3464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,323 in reported general payments places this provider in the 55th percentile of 46 allergy & immunology providers in South Carolina.

See all allergy & immunology providers in South Carolina

Medicare billing

Part B allowed, 2024
$428,630
Medicare patients
430
Services billed
20,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$83,665
Dupixent SyringeDupilumab22$83,088
Breo ElliptaFluticasone/Vilanterol96$49,896
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$20,817
SymbicortBudesonide/Formoterol Fumarate48$16,294
Arnuity ElliptaFluticasone Furoate36$16,006
Qvar RedihalerBeclomethasone Dipropionate40$13,998
Epinephrine69$11,357
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$9,380
XhanceFluticasone Propionate12$7,780
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$7,428
Ipratropium Bromide123$6,216
Wixela InhubFluticasone Propion/Salmeterol28$5,357
Fluticasone Propionate242$5,188
Albuterol Sulfate HfaAlbuterol Sulfate179$4,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$711$149,566220 claims
AstraZenecaBreztri Aerosphere, Symbicort$975$37,11169 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$60$13,99840 claims
Hikma Pharmaceuticals USAEpinephrine$15$11,35769 claims
Optinose US, Inc.Xhance$427$7,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 46 allergy & immunology providers in South Carolina.

Other allergy & immunology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →